Hybridize immunogenic tumor derived exosome (TEX) with CCR7 retained dendritic cell membrane vesicle (DCMV), and adjuvanted by MPLA, to develop a novel nanovaccine (Hy‐M‐Exo), which can target in lymph nodes via the CCR7‐CCL21 way. The gene discussed is CCR7; the disease is neoplasm.